DE60137949D1 - Antikörper, immunoassay und verfahren zum nachweis von prostatakrebs - Google Patents

Antikörper, immunoassay und verfahren zum nachweis von prostatakrebs

Info

Publication number
DE60137949D1
DE60137949D1 DE60137949T DE60137949T DE60137949D1 DE 60137949 D1 DE60137949 D1 DE 60137949D1 DE 60137949 T DE60137949 T DE 60137949T DE 60137949 T DE60137949 T DE 60137949T DE 60137949 D1 DE60137949 D1 DE 60137949D1
Authority
DE
Germany
Prior art keywords
pca
patients
psa
antibody
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60137949T
Other languages
English (en)
Inventor
Kim Pettersson
Hans Lilja
Timo Loevgren
Pauliina Niemelae
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arctic Partners Oy AB
Original Assignee
Arctic Partners Oy AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arctic Partners Oy AB filed Critical Arctic Partners Oy AB
Application granted granted Critical
Publication of DE60137949D1 publication Critical patent/DE60137949D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60137949T 2000-09-27 2001-09-26 Antikörper, immunoassay und verfahren zum nachweis von prostatakrebs Expired - Lifetime DE60137949D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20002127A FI20002127A0 (fi) 2000-09-27 2000-09-27 Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
PCT/FI2001/000834 WO2002027323A1 (en) 2000-09-27 2001-09-26 Novel antibody, immunoassay and method for prostate cancer detection

Publications (1)

Publication Number Publication Date
DE60137949D1 true DE60137949D1 (de) 2009-04-23

Family

ID=8559172

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60137949T Expired - Lifetime DE60137949D1 (de) 2000-09-27 2001-09-26 Antikörper, immunoassay und verfahren zum nachweis von prostatakrebs

Country Status (9)

Country Link
US (1) US7872104B2 (de)
EP (1) EP1320756B1 (de)
JP (1) JP5254517B2 (de)
AT (1) ATE425460T1 (de)
AU (1) AU2001291911A1 (de)
DE (1) DE60137949D1 (de)
ES (1) ES2322432T3 (de)
FI (1) FI20002127A0 (de)
WO (1) WO2002027323A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103495439B (zh) 2007-05-04 2015-09-16 欧普科诊断有限责任公司 流体连接器和微流体系统
ES2812260T3 (es) 2009-02-02 2021-03-16 Opko Diagnostics Llc Estructuras para controlar la interacción de luz con dispositivos microfluídicos
CA2853705C (en) * 2011-10-25 2021-10-12 Memorial Sloan-Kettering Cancer Center Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer
EP2771037B1 (de) 2011-10-28 2016-08-03 Fredax AB Therapeutische wirkstoffe und ihre verwendung
BR112014021776B1 (pt) * 2012-03-05 2022-08-09 Opko Diagnostics, Llc Sistema de ensaio e método para a determinação de uma probabilidade de um evento associado com o câncer da próstata
JP6312141B2 (ja) * 2012-03-30 2018-04-18 国立大学法人京都大学 前立腺がん検査用尿中バイオマーカー
KR102442738B1 (ko) 2013-11-19 2022-09-15 프레닥스 에이비 인간화된 안티 칼리크레인-2 항체
SG10201808585TA (en) * 2014-03-28 2018-11-29 Opko Diagnostics Llc Compositions and methods related to diagnosis of prostate cancer
ES2867798T3 (es) 2015-03-27 2021-10-20 Opko Diagnostics Llc Estándares del antígeno prostático y usos de estos
EP3922265A1 (de) * 2015-10-05 2021-12-15 Fredax AB Humanisierte anti psa (5a10) antikörper
CN109991405B (zh) * 2017-12-29 2023-01-24 上海索昕生物科技有限公司 一种免疫检测试剂盒及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0635575A1 (de) * 1993-07-22 1995-01-25 Wallac Oy Monoklonale Antikörper gegen Epitope in freiem uber nicht in Alpha-1-antichymotrypsin komplexiertem Prostata spezifisches Antigen
US6143509A (en) * 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
JPH10150999A (ja) * 1996-11-22 1998-06-09 Eiken Chem Co Ltd ヒト前立腺特異抗原−α１−アンチキモトリプシン複合体に対するモノクローナル抗体及びそれを用いたヒト前立腺特異抗原−α１−アンチキモトリプシン複合体の免疫学的検出法
US5858685A (en) * 1997-03-21 1999-01-12 The Board Of Trustees Of The Leland Stanford Junior University Prostate specific antigen from benign prostatic hyperplasia and its use in diagnosis
US7659073B2 (en) * 1997-04-30 2010-02-09 Hybritech Incorporated Forms of prostate specific antigens and methods for their detection
CA2286090C (en) * 1997-04-30 2013-01-08 Hybritech Incorporated Forms of prostate specific antigen and methods for their detection
US7211397B2 (en) * 1999-04-30 2007-05-01 Beckman Coulter, Inc. Method of analyzing non-complexed forms of prostate specific antigen in a sample to improve prostate cancer detection
US6482599B1 (en) * 1999-04-30 2002-11-19 Hybritech Incorporated Forms of prostate specific antigen (PSA) specific for benign prostatic hyperplasia (BPH) and methods of using such
US6423503B1 (en) * 1999-04-30 2002-07-23 Hybritech Incorporated Forms of free prostate-specific antigen (PSA) and their association with prostate tissues from prostate peripheral zone and transition zone

Also Published As

Publication number Publication date
US7872104B2 (en) 2011-01-18
WO2002027323A1 (en) 2002-04-04
ATE425460T1 (de) 2009-03-15
US20040101914A1 (en) 2004-05-27
AU2001291911A1 (en) 2002-04-08
EP1320756B1 (de) 2009-03-11
EP1320756A1 (de) 2003-06-25
JP5254517B2 (ja) 2013-08-07
ES2322432T3 (es) 2009-06-22
FI20002127A0 (fi) 2000-09-27
JP2004509934A (ja) 2004-04-02

Similar Documents

Publication Publication Date Title
Mönig et al. Expression of MMP‐2 is associated with progression and lymph node metastasis of gastric carcinoma
Xing et al. Neuroendocrine cells in human prostate over‐express the anti‐apoptosis protein survivin
Fritzsche et al. ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer
Chan et al. Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen
Fritzsche et al. ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression
DE60137949D1 (de) Antikörper, immunoassay und verfahren zum nachweis von prostatakrebs
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
DE69942742D1 (de) Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs
ATE524196T1 (de) An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür
HUP9701717A2 (hu) Eljárás cPSA-meghatározására
DE69940436D1 (de) Prostata stammzellantigen (psca) und dessen verwendungen
UA90082C2 (ru) Выделенное моноклональное антитело человека, которое специфически связывается с cd25 человека и ингибирует связывание il-2 с cd25
EA023466B1 (ru) Способ определения стволовых клеток рака молочной железы и применение антагонистов cxcr1 для лечения рака
DE69937835D1 (de) Antikörper für apoptosemarker und anwendungsverfahren
WO2003024191A3 (en) Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
ATE412756T1 (de) Verfahren zur krebsdiagnose mittels eines chimärischen toxin
AU2007317753B2 (en) Differential gene expression in physiological and pathological angiogenesis
Zargaran et al. Immunohistochemical evaluation of type IV collagen and laminin‐332 γ2 chain expression in well‐differentiated oral squamous cell carcinoma and oral verrucous carcinoma: a new recommended cut‐off
ATE283483T1 (de) Tumorenspezifisches p450 protein
Moul et al. Immunohistologic detection of prostate cancer pelvic lymph node micrometastases: correlation to preoperative serum prostate-specific antigen
ATE491727T1 (de) Zusammensetzungen und deren verwendungen zur identifizierung und zum targetting von provasopressinexprimierenden krebszellen
ATE404676T1 (de) Prostat-spezifisches-antigenformen und verfahren zu ihrer bestimmung
WO2002023200A3 (en) Human breast cancer biomarkers
WO2002063048A3 (en) Methods for predicting sensitivity of tumors to arginine deprivation
Lilja et al. Measurements of proteases or protease system components in blood to enhance prediction of disease risk or outcome in possible cancer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition